塞德斯医疗2026年研发里程碑公布，Barzol药物III期试验成焦点

Core Viewpoint - Cedars Medical (CLDX.US) has announced its key R&D plans for 2026, focusing on multiple clinical trial advancements and platform validation [1] Project Advancement - The Phase III clinical trial for CSU: The main drug Barzol targeting chronic spontaneous urticaria (CSU) is expected to complete patient enrollment by July 2026, which is the most anticipated event by management [2] - Update on the bispecific project CDX622: Data from the multi-dose escalation study is expected to be released in the third quarter of 2026. Results from the subcutaneous single-dose escalation study are also planned for release within 2026. The company aims to initiate mechanism validation studies for severe asthma based on these data [4] - Evaluation of new indications: The company will start assessing the potential for expanding Barzol into new indications such as food allergies and allergic rhinitis [5] Product Development Progress - Announcement of Phase II clinical data: Results from the Phase II studies on nodular prurigo and atopic dermatitis are planned for release in 2026. These studies will be used to determine the dosing regimen for subsequent registration studies [3] Strategic Advancement - Mid to long-term strategic focus: The company is committed to validating its bispecific platform (CDX622) and promoting Barzol as the preferred drug in the CSU and other disease areas. In terms of commercialization, the plan is to independently advance in the U.S. market while considering partnerships for markets outside the U.S. [6]